[Use of xalatan in unstable glaucoma in myopic patients].
41 patients (79 eyes), their age averaged 66.9 +/- 4.5 years were divided into two groups. Group 1 consisted of 20 patients (39 eyes) with primary open-angle glaucoma (POAG), with refraction emmetropy (1.0 D, group 2 included 11 cases (22 eyes) in combination with myopia, group 3 included 10 patients (19 eyes) with normotensive glaucoma (NTG) and myopia. In the patients with unstabilized POAG in combination with myopia, NTG and myopia monotherapy with Xalatan (latanoprost) or combined therapy with xalatan with beta-blockers, and to a lesser extent, with Pilocarpine, was shown to stabilize the process in 35-53% of cases.
Makashova
N V
NV
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000368:Aged; D005901:Glaucoma / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077338:Latanoprost; D008875:Middle Aged; D009216:Myopia / Q000150:complications / Q000188:drug therapy*; D010862:Pilocarpine / Q000008:administration & dosage / Q000627:therapeutic use; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D011461:Prostaglandins F, Synthetic; D010862:Pilocarpine; D000077338:Latanoprost